⁠App Economy Insights
Zillow co-founder Spencer Rascoff’s new startup, Pacaso (they’re sponsoring us), is disrupting the $1.3T vacation home market.

Backed by Softbank
$110M+ in gross profits
Nasdaq ticker $PCSO reserved

Invest for just $2.80/share by midnight PT.👇https://t.co/83auTLIETd
tweet

⁠Capital Employed
49 ‘fresh-off-the-press’ stock pitches we’ve enjoyed reading in the past two weeks 👇

https://t.co/R8JChwVNsJ https://t.co/4tSCje8oq1
tweet

⁠Wall St Engine
Today's Key Events (All EST) — 05/30/2025

08:30: US PCE Price Index
08:30: US Consumer Spending / Personal Income
08:30: US Wholesale Inventories
09:45: US Chicago PMI
10:00: University Michigan Sentiment Final
12:20: Fed's Bostic
17:45: Fed's Daly
19:30: Fed's Goolsbee
tweet

⁠Wall St Engine
WSJ reports Trump’s team is preparing a fallback tariff plan if courts strike down the current approach. They’re eyeing Section 122 of the 1974 Trade Act, which allows up to 15% tariffs for 150 days. The move would buy time to build a more legally durable case under Section 301. https://t.co/Csw7B89om1
tweet

⁠Wall St Engine
TRUMP TO HOLD PRESS CONFERENCE WITH ELON MUSK FRIDAY AT 1:30 P.M. ET
tweet

⁠Wall St Engine
Treasury Sec. Bessent says US-China trade talks are “a bit stalled” and may need a Trump-Xi call to move forward. Bessent expects more talks in the next few weeks. https://t.co/MRKHZtatZL
tweet

⁠Wall St Engine
U.S. CORPORATE PROFITS DROP 2.9% IN Q1 — the sharpest fall since 2020, per BEA. https://t.co/GY4ik9DeAH
tweet

⁠Wall St Engine
Saudi utility ACWA Power has signed preliminary deals in Malaysia to explore $10B worth of renewable energy, green hydrogen, and water projects by 2040. The agreements cover around 13GW in capacity and aim to help Malaysia hit 70% renewable energy by mid-century
tweet

⁠Wall St Engine
Piper Sandler Downgrades $ZS to Neutral from Overweight, Raises PT to $260 from $235

Analyst comments: "While the year appears to be playing out as we had hoped, with the company topping 3Q metrics and the back half billings ramp appearing less daunting given quarterly performance, the recent run in shares (+30% over past 3 months) have us mulling upside from here. Especially in light of integrating an acquisition, a pending guide for the coming FY (ARR-based which could dip below the 20% threshold) and looming Fed uncertainty. We don't think investors should chase what has been solid performance (fundamentals and stock) and should look for more compelling entry points to buy shares. Downgrading to Neutral with a $260 target."

Analyst: Ron Owens
tweet

⁠Wall St Engine
Synopsys $SNPS has told staff in China to stop all sales, services, and new orders following new U.S. export restrictions, per an internal memo seen by Reuters. https://t.co/J2NgQ6dbo5
tweet

⁠Wall St Engine
Barclays Upgrades $ROK to Overweight from Equalweight, Raises PT to $350 from $283

Analyst comments: "The main drivers are: 1) Why now? The top-line outlook appears firmer... We had upgraded our rating on ROK to EW from UW in late 2024 in our 2025 Outlook report, as we thought its top line was likely to bottom in 2025 after a very weak 2024, and the stock had underperformed its main Automation peer (EMR) substantially in 2024. However, we did not move to an outright OW rating, because we thought the timing of the top-line trough was very uncertain, amidst uncertainty around the extent of further de-stocking needed by its customers / distributors. Today, while there is a high degree of macro uncertainty, it does seem as if the de-stocking that was under way for much of the past 18 months for some of ROK’s main hardware products (hardware is around two-thirds of its sales, with the balance comprised of software and services) has run its course, and it does not seem as if there was an outsized degree of tariff pre-buy for its products in early 2025, based off sequential trends for ROK and its peers."

Analyst: Julian Mitchell
tweet

⁠Wall St Engine
Sanofi $SNY & Regeneron’s $REGN COPD drug Itepekimab delivered mixed results in late-stage trials—hitting its goal in one study with a 27% reduction in exacerbations, but missing the main target in another. Both are now reviewing the data and planning next steps with regulators.
tweet

⁠Wall St Engine
Ray-Ban maker EssilorLuxottica is buying Optegra, which runs 70+ eye hospitals across Europe, in a push into AI-driven eyecare. Deal builds on recent med-tech buys like Heidelberg Engineering and Cellview Imaging. https://t.co/1zTqbFLUJZ
tweet